Linagliptin
165 interactions 429 cited references
Also sold as:
Tradjenta
Tradjenta®
Trijardy® (as a combination product containing Empagliflozin, Linagliptin, Metformin)
About Linagliptin
Linagliptin is used along with diet and exercise and sometimes with other medications to lower blood sugar levels in patients with type 2 diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally). Linagliptin is in a class of medications called dipeptidyl peptidase-… Read the full Linagliptin drug information page →
Medically reviewed by
Dr. Brian Staiger, PharmD, BCPS
· Updated Aug 9, 2026
· Editorial policy
· Data sources
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Contraindicated
Linagliptin Ensitrelvir Increased CYP3A/P-gp substrate exposure and an increased risk of adverse reactions DetailsMajor
Linagliptin Abiraterone Abirtega An increased risk of severe hypoglycemia Details Linagliptin Chloroquine Aralen® Hypoglycemia Details Linagliptin Delafloxacin Baxdela Changes in blood glucose and increased risk of hypoglycemia or hyperglycemia Details Linagliptin Delafloxacin Injection Baxdela Changes in blood glucose and increased risk of hypoglycemia or hyperglycemia Details Linagliptin Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Linagliptin Furosemide Injection Disal An increased risk of hyperglycemia and an increased insulin requirement Details Linagliptin Gatifloxacin Ophthalmic Zymar® Changes in blood glucose and increased risk of hypoglycemia or hyperglycemia Details Linagliptin Gemifloxacin Factive Changes in blood glucose and increased risk of hypoglycemia or hyperglycemia Details Linagliptin Hydroxychloroquine Plaquenil Enhanced hypoglycemic effect of antidiabetics and an increased risk of hypoglycemia Details Linagliptin Insulin Degludec (Rdna Origin) Injection Ryzodeg® (as a combination product containing Insulin Degludec and Insulin Aspart) An increased risk of hypoglycemia Details Linagliptin Insulin Detemir (Rdna Origin) Injection Levemir An increased risk of hypoglycemia Details Linagliptin Insulin Glulisine (Rdna Origin) Injection Apidra An increased risk of hypoglycemia Details Linagliptin Lanreotide Injection Somatuline An increased risk of hypoglycemia and impaired glucose regulation Details Linagliptin Lenacapavir Injection Sunlenca Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Linagliptin Lenacapavir Oral Sunlenca Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Linagliptin Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Linagliptin Levofloxacin Levaquin Changes in blood glucose and increased risk of hypoglycemia or hyperglycemia Details Linagliptin Levofloxacin Injection Levaquin Changes in blood glucose and increased risk of hypoglycemia or hyperglycemia Details Linagliptin Abiraterone Acetate Abirtega An increased risk of severe hypoglycemia Details Linagliptin Abiraterone Acetate, Micronized Abirtega An increased risk of severe hypoglycemia Details Linagliptin Alfentanil Increased ALfentanil exposure and an increased risk of respiratory depression Details Linagliptin Apalutamide Erleada Reduced linagliptin exposure Details Linagliptin Artemether Increased artemether/lumefantrine exposure, an increased risk of QT prolongation, reduced CYP3A4 substrate exposure and reduced ef... Details Linagliptin Avacopan Tavneos Increased CYP3A4 substrate exposure Details Linagliptin Berotralstat Orladeyo Increased P-gp substrate exposure Details Linagliptin Carbamazepine Carbatrol Reduced linagliptin exposure Details Linagliptin Chlorothiazide Diuril An increased risk of hyperglycemia and an increased insulin requirement Details Linagliptin Chlorthalidone Hemiclor An increased risk of hyperglycemia and an increased insulin requirement Details Linagliptin Ciprofloxacin Changes in blood glucose and increased risk of hypoglycemia or hyperglycemia Details Linagliptin Clarithromycin Biaxin Increased exposure of CYP3A4 substrate and risk for toxicity Details Linagliptin Conivaptan Vaprisol Increased CYP3A substrate exposure Details Linagliptin Efavirenz Reduced linagliptin exposure Details Linagliptin Enoxacin Changes in blood glucose and increased risk of hypoglycemia or hyperglycemia Details Linagliptin Enzalutamide Xtandi Reduced linagliptin exposure Details Linagliptin Erythromycin Erythrocin Stearate Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details Linagliptin Fosphenytoin Cerebyx Reduced linagliptin exposure Details Linagliptin Furosemide Disal An increased risk of hyperglycemia and an increased insulin requirement Details Linagliptin Gatifloxacin Zymaxid Changes in blood glucose and increased risk of hypoglycemia or hyperglycemia Details Linagliptin Grepafloxacin Changes in blood glucose and increased risk of hypoglycemia or hyperglycemia DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacistEducational information only, not medical advice. Always confirm interactions with your pharmacist
or prescriber before making any change to your medications.